Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells

Biochemical Pharmacology

Volumn 70, Issue 3, 2005, Pages 426-432

  Sarkar, Malancha ^a   Han, Tieran ^a   Damaraju, Vijaya ^b   Carpenter, Pat ^b   Cass, Carol E ^b   Agarwal, Ram P ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Arabinosylcytosine; Cellular resistance; Deoxycytidine kinase; Human lymphoid cells; Nucleoside transport; Sp1; Transcription factor

Indexed keywords

CLADRIBINE; CYTARABINE; DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLUDARABINE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEOSIDE; NUCLEOSIDE DERIVATIVE; NUCLEOSIDE TRANSPORTER; THIACYTIDINE; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; ZALCITABINE;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOID CELL; PRIORITY JOURNAL;

CELL LINE; CYTARABINE; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE-NUCLEOSIDE TRANSPORTER 2; HUMANS; LYMPHOCYTES; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR;

EID: 21344452604     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.05.014     Document Type: Article

References (48)

1. B.D. Cheson New antimetabolites in the treatment of human malignancies Semin Oncol 19 1992 695 706
2. T. Robak Purine nucleoside analogues in the treatment of myeloid leukemias Leuk Lymphom 44 2003 391 409
3. E. De Clercq New development in anti-HIV chemotherapy Curr Med Chem 8 2001 1543 1572
4. J.A.M. Van Laar, J.M. Rustum, S.P. Ackland, C.J. Van Groeningen, and G.J. Peters Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer Eur J Cancer 34 1997 296 306
5. M.J. Keating, K.B. McCredie, G.P. Bodey, T.L. Smith, E.A. Gehan, and E.J. Freireich Improved prospects for long-term survival in adults with acute myelogenous leukaemia JAMA 248 1982 2481 2486
6. Y.M. Rustum, and H.D. Preisler Correlation between leukemic cell retention of 1-β-arabinofuranosylcytosine 5′-triphosphate and response to therapy Cancer Res. 39 1979 42 49
7. J.S. Wiley, S.P. Jones, W.H. Sawyer, and AR.P. Paterson Cytosine arabinoside influx and nucleoside transport sites in acute leukemias J Clin Invest 69 1982 479 489
8. T.C. Chou, Z. Arlin, B.D. Clarkson, and F.S. Philips Metabolism of 1-β-d-arabinofuranosyl cytosine in human leukemic cells Cancer Res 37 1977 3561 3570
9. A. Fridland Inhibition of deoxyribonucleic acid chain initiation: a new mode of action of 1-β-d-arabinofuranosylcytosine in human lymphoblasts Biochemistry 16 1977 5308 5312
10. G.J. Kaspers, C.M. Zwaan, A.J. Veerman, M.G. Rots, R. Pieters, and P. Bucsky Cellular drug resistance in acute myeloid leukemia: literature review and preliminary analysis of an ongoing collaborative study Klin Padiatr 11 1999 239 244
11. S. Yamada, T. Hongo, S. Okada, C. Watanabe, Y. Fujii, and T. Ohzeki Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia Leukemia 15 2001 1892 1897
12. C.D. Steuart, and P.J. Burke Cytidine deaminase and the development of resistance to arabinosylcytosine Nature (London) 233 1971 109 110
13. D. Kessel, T.C. Hall, and D. Rosenthal Uptake and phosphorylation of cytosine arabinoside by normal and leukemic human blood cells in vitro Cancer Res 29 1969 459 463
14. M.H. Tattersall, K. Ganeshaguru, and A.V. Hoffbrand Mechanisms of resistance of human acute leukemia cells to cytosine arabinoside Br J Haematol 27 1974 39 46
15. J.M. Barret, and B.T. Hill DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets Anticancer Drugs 9 1998 105 123
16. V. Gandhi, E. Estey, M.J. Keating, A. Chucrallah, and W. Plunckett Chloro-deoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions Blood 87 1996 256 264
17. R.P. Agarwal, T. Han, and M. Fernandez Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance Biochem Pharmacol 61 2001 39 47
18. T. Han, M. Fernandez, M. Sarkar, and R.P. Agarwal Arabinosylcytosine downrgulates thymidine kinase and induces cross-resistance to zidovudine in T-lymphoid cells Biochem Biophys Res Commun 307 2003 564 568
19. R.P. Agarwal, T. Han, and M. Fernandez Collateral resistance of a dideoxycytidine resistant cells line to 5′-fluoro-2′-deoxyuridine Biochem Biophys Res Commun 262 1999 657 660
20. R.S. Mani, J.R. Hammond, J.M. Marjan, K.A. Graham, J.D. Young, and S.A. Baldwin Demonstration of equilibrative nucleoside transporters (hENT1 and hENT2) in nuclear envelop of cultured human choriocarcinoma (Be Wo) cells by functional reconstitution in proteoliposomes J Biol Chem 273 1998 30818 30825
21. M.F. Vickers, R.S. Mani, M. Sundaram, D.L. Hogues, J.D. Young, and S.A. Baldwin Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae. Interaction of inhibitors of nucleoside transport with recombinant hENT1 and a glycosylation-defective derivative (hENT1/N48Q) Biochem J 339 1999 21 32
22. L.L. Jennings, C. Hao, M.A. Cabrita, M.F. Vickers, S.A. Baldwin, and J.D. Young Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system Neuropharmacol 40 2001 722 731
23. E. Schreiber, P. Matthias, M.M. Muller, and W. Schaffner Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells Nucleic Acids Res. 17 1989 6419
24. E.H. Chen, E.E. Johnson, S.M. Vetter, and B.S. Mitchell Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines J Clin Invest 95 1995 1660 1668
25. M. 25 Pastor-Anglada, P. Cano-Soldado, M. Molina-Arcas, M.P. Lostato, I. Larrayoz, and J. Martinaz-Picado Cell entry and export of nucleoside analogs Virus Res 107 2005 151 164
26. M. Pastor-Anglada, F.J. Casado, R. Valdes, J. Mata, J. Garcia-Manteiga, and M. Molina Complex regulation of nucleoside transporter expression in epithelial and immune system cells Mol Membr Biol 18 2001 81 85
27. +-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selected for purine and pyrimidine nucleosides (system cib) J Biol Chem 276 2001 2914 2927
28. C.M. Galmarini, J.R. Mackey, and C. Dumontet Nucleoside analogues: mechanisms of drug resistance and reversal strategies Leukemia 15 2001 875 890
29. W.P. Gati, A.R. Paterson, A.R. Belch, V. Chlumecky, L.M. Larrat, and M.J. Mant Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC) Leuk Lymphoma 32 1998 45 54
30. B. Groschel, A. Kaufmann, G. Hover, J. Cinatl, H.W. Doerr, and P. Noordhuis 3′-Azido-2′,3′-dideoxythymidine induced deficiency of thymidine kinases 1, 2 and deoxycytidine kinase in H9 T-lymphoid cells Biochem Pharmacol 64 2002 239 246
31. D.A. Carson, D.B. Wasson, J. Kaye, B. Ullman, D.W. Martin Jr., and R.K. Robins Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo Proc Natl Acad Sci USA 77 1980 6865 6869
32. V. Gregoire, J.F. Rosier, M. De Bast, M. Bruniaux, B. De Coster, and M. Octave-Prignot Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro Radiother Oncol 63 2002 329 338
33. C.M. Beausejour, J. Gagnon, M. Primeau, and R.L. Momparler Cytotoxic activity of 2′,2′-difluorodeoxycytidine, 5-aza-2′- deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene Biochem Biophys Res Commun 293 2002 1478 1484
34. J.K. Owens, D.S. Shewach, B. Ullman, and B.S. Mitchell Resistance to 1-beta-d-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene Cancer Res 52 1992 2389 2393
35. H. Kawasaki, C.J. Carrera, L.D. Piro, A. Saven, T.J. Kipps, and D.A. Carson Relationship of deoxycytidine kinase and cytoplasmic 5′- nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine Blood 81 1993 597 601
36. A.P. Stegmann, W.H. Honders, R. Willemze, H. Ruiz, and J.E. Landegent Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity Blood 85 1995 1188 1194
37. X.B. Kong, W.P. Tong, and T.C. Chou Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine Mol Pharmacol 39 1991 250 257
38. P.A. Leegwater, R.A. De Abreu, and F. Albertioni Analysis of DNA methylation of the 5′ region of the deoxycytidine kinase gene in CCRF-CEM-sensitive and cladribine (CdA)- and 2-chloro-2′-arabino-fluoro- 2′-deoxyadenosine (CAFdA)-resistant cells Cancer Lett 130 1998 169 173
39. V.I. Avramis, R.A. Mecum, J. Nyce, D.A. Steele, and J.S. Holcenberg Pharmacodynamic and DNA methylation studies of high-dose 1-beta-d- arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukaemia Cancer Chemother Pharmacol 24 1989 203 210
40. E.G. Chottiner, D.S. Shewach, N.S. Datta, E. Ashcraft, D. Gribbin, and D. Ginsburg Cloning and expression of human deoxycytidine kinase cDNA Proc Natl Acad Sci USA 88 1991 1531 1535
41. M.J. Veuger, M.H. Heemskerk, M.W. Honders, R. Willemze, and R.M. Barge Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells Blood 99 2002 1373 1380
42. M. Staub, Z. Csapo, T. Spasokukotskaja, and M. Sasvari-Szekely Deoxycytidine kinase can be also potentiated by the G-protein activator NaF in cells Adv Exp Med Biol 431 1998 425 428
43. J.W. Taub, X. Huang, L.H. Matherly, M.L. Stout, S.A. Buck, and G.V. Massey Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin Blood 94 1999 1393 1400
44. N.S. Datta, D.S. Shewach, B.S. Mitchell, and I.H. Fox Kinetic properties and inhibition of human T lymphoblast deoxycytidine kinase J Biol Chem 264 1989 9359 9364
45. Y. Ge, T.L. Jensen, L.H. Matherly, and J.W. Taub Physical and functional interactions between USF and Sp1 proteins regulate human deoxycytidine kinase promoter activity J Biol Chem 278 2003 49901 49910
46. M. Johansson, A. Norda, and A. Karlsson Conserved gene structure and transcription factor sites in the human and mouse deoxycytidine kinase genes FEBS Lett 487 2000 209 212
47. S.S. Arcot, and P.L. Deininger Protein binding sites within the human thymidine kinase promoter Gene 111 1992 249 254
48. D.S. Choi, M. Handa, H. Young, A.S. Gordon, I. Diamond, and R.O. Messing Genomic organization and expression of the mouse equilibrative, nitrobenzylthioinosine-sensitive nucleoside transporter 1 (ENT1) gene Biochem Biophys Res Commun 277 2000 200 208